Literature DB >> 7723238

A genetic model of malignant phase hypertension in rats.

C E Whitworth1, S Fleming, Y Kotelevtsev, L Manson, G A Brooker, A D Cumming, J J Mullins.   

Abstract

A genetic model of malignant phase hypertension in rats is described which closely parallels the natural history of untreated human malignant phase hypertension. Although the factors initiating transition from essential hypertension to the accelerated phase in humans remain unknown, we report the characteristics of a genetically determined and reproducible phenotype which was found to result from a cross between hypertensive transgenic Ren-2 rats and normotensive Sprague-Dawley (Edinburgh) rats. Male F1 hybrids developed malignant phase hypertension with a penetrance of 73.5% (95% confidence limits 65.7 to 81.3%) by 100 days of age. Phenotypic features included an accelerated rise in blood pressure, fibrinoid necrosis, activation of the renal renin-angiotensin system and microangiopathic hemolytic anemia. In an analytical cross no significant difference in blood pressure was observed between malignant phase and non-malignant phase animals prior to transition, implying that a factor in addition to hypertension appears necessary for inducing transition to the malignant phase phenotype. Segregation of the malignant phenotype suggested that susceptibility is determined by at most two genetic loci.

Entities:  

Mesh:

Year:  1995        PMID: 7723238     DOI: 10.1038/ki.1995.66

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Carlo J Milani; Hiroyuki Kobori; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-11       Impact factor: 2.378

2.  Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic rats.

Authors:  Catherine G Howard; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-06       Impact factor: 2.378

3.  AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren2 transgenic rats fed with a high-salt diet.

Authors:  Dustyn E Williams; Minolfa C Prieto; John J Mullins; L Gabriel Navar; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-04       Impact factor: 2.378

4.  Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Miguel L Graciano; Kenneth D Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-05

5.  20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Lenka Sedláková; Soňa Kikerlová; Zuzana Husková; Lenka Červenková; Věra Čertíková Chábová; Josef Zicha; John R Falck; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Vojtěch Krátký; Luděk Červenka; Libor Kopkan
Journal:  Biosci Rep       Date:  2018-09-12       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.